SAG and chronic myelogenous leukemia, BCR-ABL1 positive: The top scoring candidates included Nilotinib and Imatinib, two protein kinase inhibitors used to treat chronic myelogenous leukemia[34]; their docking scores were comparable to those of the known SMO modulators Vismodegib and SAG.